United Therapeutics (UTHR) Depreciation & Amortization (CF) (2009 - 2026)

United Therapeutics has disclosed Depreciation & Amortization (CF) across 18 years of filings, most recently posting $22.6 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $22.6 million, up 14.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $88.4 million (up 14.36% YoY), and the FY2025 annual result was $85.6 million, up 18.07% from the prior year.
• Depreciation & Amortization (CF) came in at $22.6 million for Q1 2026 at United Therapeutics, down from $22.8 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $22.8 million in Q4 2025 to a low of $12.5 million in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $15.0 million (2024), against an average of $16.8 million.
• Across the five-year window, Depreciation & Amortization (CF) changed 0.0% in 2022 and jumped 44.96% in 2024, its largest moves.
• United Therapeutics' Depreciation & Amortization (CF) stood at $13.2 million in 2022, then gained by 3.79% to $13.7 million in 2023, then surged by 43.8% to $19.7 million in 2024, then rose by 15.74% to $22.8 million in 2025, then slipped by 0.88% to $22.6 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $22.6 million (Q1 2026), $22.8 million (Q4 2025), and $21.9 million (Q3 2025), per Business Quant data.